单唾液酸四己糖神经节苷脂联合醒脑静注射液治疗急性脑出血临床研究

Curative effect of monosialotetrahexosylganglioside combined with Xingnaojing injection on acute cerebral hemorrhage

共120例急性脑出血患者分别予醒脑静注射液单药治疗(对照组,60例)或单唾液酸四己糖神经节苷脂联合醒脑静注射液治疗(联合治疗组,60例),治疗21 d后评价出血量和神经功能改善程度。结果显示,治疗后两组患者出血量和美国国立卫生研究院卒中量表(NIHSS)评分均低于治疗前(均P=0.000),且联合治疗组优于对照组(均P=0.000)。提示对于急性脑出血患者,单唾液酸四己糖神经节苷脂联合醒脑静注射液治疗可以显著改善患者神经功能,临床疗效肯定。

This paper aims to observe the curative effect of monosialotetrahexosylganglioside combined with Xingnaojing injection on acute cerebral hemorrhage. A total of 120 cases with acute cerebral hemorrhage were treated with Xingnaojing injection monotherapy （control group, N = 60） or monosialotetrahexosylganglioside combined with Xingnaojing injection （combined treatment group, N = 60）. Bleeding amount and National Institutes of Health Stroke Scale （NIHSS） scores of 2 groups were both significantly reduced on the 21th day after treatment （P = 0.000, for all）, but bleeding amount and NIHSS scores in combined treatment group were significantly lower than those in control group （P = 0.000, for all）. After 21 d treatment, total effective rate of combined treatment group was 86.67% （52/60）, which was significantly higher than that of control group [66.67% （40/60）; χ5 = 1.493, P = 0.024]. For patients with acute cerebral hemorrhage, monosialotetrahexosylganglioside combined with Xingnaojing injection can significantly improve the neurological function.